June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Utilisation of Machine Learning to quantify fluid volume of wet age-related macular degeneration (wARMD) patients based on swept-source optical coherence tomography (SS-OCT) imaging: The ONTARIO Study
Author Affiliations & Notes
  • Simrat Kaur Sodhi
    University of Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Jonathan D. Oakley
    Voxeleron, San Francisco, California, United States
  • Daniel B. Russakoff
    Voxeleron, San Francisco, California, United States
  • Netan Choudhry
    Vitreous Retina Macula Specialists of Toronto, Etobicoke, Ontario, Canada
    Department of Ophthalmology & Visual Sciences, University of Toronto, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships   Simrat Sodhi, None; Jonathan Oakley, Voxeleron (E); Daniel Russakoff, Voxeleron (E); Netan Choudhry, Allergan (S), Allergan (C), Bayer (S), Bayer (C), Bayer (R), Carl Zeiss Meditec (C), Novartis (S), Novartis (C), Optos (S), Optos (C), Optos (R)
  • Footnotes
    Support  Research Grant from Bayer Canada
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2150. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Simrat Kaur Sodhi, Jonathan D. Oakley, Daniel B. Russakoff, Netan Choudhry; Utilisation of Machine Learning to quantify fluid volume of wet age-related macular degeneration (wARMD) patients based on swept-source optical coherence tomography (SS-OCT) imaging: The ONTARIO Study. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2150.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Evaluate the predictive ability of a deep learning-based, automated, macular fluid segmentation algorithm to determine long-term visual acuity (VA) outcomes in wet age-related macular degeneration (wARMD) patients using baseline swept-source optical coherence tomography (SS-OCT) and OCT-angiography (OCT-A) data.

Methods : Twenty-two SS-OCT volumes of the macula, comprising 5,632 images from 22 wARMD subjects were used to assess retinal layer thicknesses, quantify intraretinal fluid (IRF), subretinal fluid (SRF) and fluid in serous pigment epithelium detachments (PED). Layer thicknesses were manually corrected and fluid segmentation was performed using a novel, deep learning algorithm with results validated relative to two expert graders. OCT-A data was used to manually define the extent of the choroidal neovascularization (CNV) in each scan. Patients received 2 mg of intravitreal aflibercept injections monthly for 3 months, then bimonthly for 12 months. Baseline OCT morphological features and measurements were correlated using the Pearson correlation coefficient (PCC) to changes in VA to determine which features impacted the long-term visual outcomes.

Results : Total fluid volume at baseline and change in LogMar at week 52 relative to baseline had the closest correlation (PCC=0.652, p=0.005). Fluid was subsequently sub-categorized into IRF, SRF and PED, with PED volume having the next highest correlation (PCC=0.648, p=0.005). Average total retinal thickness in isolation gave a lower correlation (PCC=0.334, p=0.189), and mean CNVM size (um2) from 3 mm OCT-A scans was very low (PCC=0.072, p=0.784). When two features were combined and correlated with visual outcomes, the best correlation increased to PCC=0.695 (p=0.002) using mean CNVM size and total fluid volume.

Conclusions : In isolation, total fluid volume best correlates with change in LogMar values between baseline and week 52. In combination with complimentary information from OCT-A, an improvement in the linear correlation score was observed. Average total retinal thickness provided a lower correlation and thus provides a lower predictive outcome than other metrics assessed. Clinically, a machine-learning approach to analyzing fluid metrics combined with lesion size may provide an advantage in personalizing therapy predicting VA outcomes.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×